Figure 2
Figure 2. Kaplan-Meier curve of overall survival in patients with chronic-phase CML with T315I mutation treated with omacetaxine. (A) Patients who achieved CHR compared to those who did not achieve CHR, and (B) patients who achieved MCyR compared to those who did not achieve MCyR.

Kaplan-Meier curve of overall survival in patients with chronic-phase CML with T315I mutation treated with omacetaxine. (A) Patients who achieved CHR compared to those who did not achieve CHR, and (B) patients who achieved MCyR compared to those who did not achieve MCyR.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal